From: Palbociclib plus endocrine therapy in hormone receptor-positive and HER2 negative metastatic breast cancer: a multicenter real-world study in the northwest of China
Start dose of Palbociclib (mg/day)
 Subtotal
211(100)
  Start at 125
181(85.8)
  Start at 100
29(13.7)
  Start at 75
1(0.5)
Dose reduction (mg/day)
32(15.2)
  From 125 to 100
21(10.0)
  From 100 to 75
11(5.2)